{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P05164",
      "entity_text" : "MPO",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:77999",
      "entity_text" : "rosiglitazone",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Treatment with rosiglitazone for 12 weeks significantly decreased serum MPO activity and increased serum PON1 activity in this model.",
  "reading_complete" : "2020-08-03T16:55:29Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T16:54:20Z",
  "trigger" : "decreased",
  "evidence" : [ "rosiglitazone for 12 weeks significantly decreased serum MPO" ],
  "pmc_id" : "4314417",
  "score" : 0
}